wax --> TradingTips - 500 Beiträge pro Seite

[waxweazle]

Hallo,

Nach Wunsch von einigen mache ich jetzt diesen Threat auf für weiter
Aktientrading Tips.

Ich werde hier nur die Werte posten mehr nicht.
Jeder weis selber was er machen soll ob er rein soll oder nicht und mit wieviel...
Wie bei allem ist das die Sache von euch..

Gruss
Wax


p.s. der MillionThreat läuft ganz normal weiter

[waxweazle]

Antwort auf Beitrag Nr.: 37.655.018 von waxweazle am 27.07.09 20:13:44

Generex Biotechnology CorporationHilfe und Infos
ISIN: US3714851033
WKN: 922012
Kürzel: GNBT

[waxweazle]

Hier noch ein paar Infos zu der Aktie


Investment Report for Generex Biotechnology Corp. (GNBT)
Submitted by admin on Saturday, 25 July 2009One Comment
Generex Biotechnology Corp. (Nasdaq: GNBT)

Generex Biotechnology Corp. (GNBT) is a development-stage biopharmaceutical company engaged in research, development and commercialization of its proprietary platform technology for oral administration to treat metabolic and immunological diseases. The Company specializes in oral (buccal) cavity administration, using a hand-held aerosol applicator, of proteins, peptides, monoclonal antibodies, hormones and vaccines.

The Company promotes four products including, Generex Oral-lyn for the treatment of type-I and type-II diabetes; Glucose RapidSpray as a glucose additive for people with glucose deficient diets; BaBoom! Energy Spray, an instant energy spray for athletes or people suffering from overall fatigue; and GlucoBreak, a glucose spray. The Company also develops a medicinal chewing gum to treat obesity and type-II diabetes mellitus as well as other products for postoperative pain. The Company markets its products through distributors and retail chains in Ecuador, Canada, Algeria, Morocco and the United States.

Founded in 1983, Generex Biotechnology Corp. is based in Toronto, Canada.

Share Statistics
23-Jul-09) 2007 2008 %
Chg Q3 2008 Q3 2009 % Chg
Symbol GNBT Revenue, $Mn 0.2 0.1 -50% 0 0 n/m
Current price $0.65 Gross marg. 50.00% 100% 0.00% n/m n/m n/m
52wk Range: $1.14-0.08 Oper. margin -13k% -33k% 33.07% n/m n/m -38.4%
Avg Vol (3m): 10,177,500 Net margin -12k% -36k% 54.04% n/m n/m 11.80%
Market Cap. 119.4M
Dil. Shares Outst. 143.5M EPS, $ -0.215 -0.326 51.63% -0.091 -0.079 -13.2%
Source: Reuters.com, SEC Filings.
Financial Summary

GNBT reported in June a net loss for its fiscal third quarter of $11.35 million, or a loss of eight cents per share, compared with a loss of $10.17 million, or a loss of nine cents, for the same quarter last year.

Revenue soared to $45,251 for the third quarter of fiscal 2009 from $1,530 for the third quarter of fiscal 2008. The Company cited rapid sales of its over-the-counter Glucose RapidSpray product for the jump in revenue.

Cost of goods sold jumped to $26,297 for the latest reported quarter, up from $639 for the same period last year. Research and development expenses dropped to $3 million, or a decline of 30.2% from the equivalent period last year. Sales and Marketing expenses decreased to $367,371, or a decline of 12.3%, legal and other expenses dropped 46.7% to $2.74 million due to a drop in accounting, consulting and traveling expenses.

There is no consensus estimate for the next earnings release.

SALES (in millions) Estimate Actual Diff. Surprise %

Quarter Ending Jul-08 1.50 0.06 1.44 96.0
Quarter Ending Apr-08 0.70 0.00 0.70 99.7
Year Ending Oct-07 0.13 0.45 0.32 246.2
Year Ending Jul-07 0.10 0.15 0.05 52.0
Earnings (per share)
Quarter Ending Jul-08 -0.08 -0.11 0.03 -37.5
Quarter Ending Apr-08 -0.06 -0.09 0.03 -50.0
Year Ending Oct-07 -0.06 -0.07 0.01 -16.7
Year Ending Jul-07 -0.05 -0.07 0.02 -40.0

Source: Reuters.com
Analyst Consensus

One analyst polled by Thomson Reuters rate shares of GNBT an “Outperform.” The details of the analysts polled are as follows:
Analyst Recommendations and Revisions
1-5 Linear Scale Current 1 Month
Ago 2 Month
Ago 3 Month
Ago
(1) BUY 0 0 0 0
(2) OUTPERFORM 1 1 1 1
(3) HOLD 0 0 0 0
(4) UNDERPERFORM 0 0 0 0
(5) SELL 0 0 0 0
No Opinion 0 0 0 0

Mean Rating 2.00 2.00 2.00 2.00
Source: Yahoo.com/finance
Investment Highlights

GNBT is a development-stage biopharmaceutical company engaged in research, development and commercialization of its proprietary platform technology for oral administration to treat metabolic and immunological diseases.

The Company operates in an approximately $21 billion oral anti-diabetic market, which is growing at roughly 6% per year. Research company Visiongain predicts continued significant market growth as the population in the OECD countries median age climbs.

Individuals with diabetes number approximately 170 million worldwide. The World Health Organization (WHO) projects that by 2025 more than 300 million people, or 6% of the world’s population, will become afflicted with diabetes–a condition that ranks sixth in the leading cause of death in the United States.

The Company’s flagship anti-diabetes product Generex Oral-lyn is available in Ecuador and is in phase III clinical trials in the United States. Oral-lyn, pending final approval from the Food and Drug Administration (FDA), will be included among 10 other competing anti-diabetes oral sprays in a multi-billion dollar worldwide market, which is expected to double within twenty years.

On July 20, the Company announced the release of a study which demonstrates the results of a novel Ii-Key/HPV immunotherapeutic vaccine, details of which appear in the July 2009 edition of trade magazine, Vaccine. The study demonstrates an additional application of the Ii-Key technology platform, which is presently developed by the Company’s solely owned subsidiary Antigen Express. Another peptide, AE37, of this application is currently in phase II trials for the treatment of breast cancer and phase I trials for the treatment of prostate cancer.

Presently, traders have been anticipating an announcement for the FDA for the Company’s phase III drug candidate Oral-lyn. If Oral-lyn clears phase III trials, the commercialization of the drug is elevated to approximately a 90% success rate.
Technical Analysis

gnbt Investment Report for Generex Biotechnology Corp. (GNBT)

Source: http://stockcharts.com/h-sc/ui

GNBT trades above its 13-day moving average. This bullish sign is even more significant because the moving average turned to a slightly positive trend in mid-July.

The MACD for GNBT currently indicates a bullish signal. The MACD is above the signal line, a 9-day moving average. The MACD is also above the critical level of 0, which implies the past price action had been to the up-side. Overall, the chart is bullish following the test of the $0.50 price level.
Comparative Analysis

Company Name Ticker Price per Mrkt. Cap. P/E P/S
Jul-21-2009 Symbol Share, $ $ Mn 2009 2010 2009 2010
CPEX Pharmaceuticals Inc. CPEX 10.86 27.0 n/a n/a 1.68 n/a
Mannkind Corp. MNKD 7.46 761.3 n/a n/a n/a n/a
Novo Nordisk A/S NVO 57.45 34,900.0 18.3 14.36 3.85 n/a
Life Technologies Corp. LIFE 41.69 7,280.0 n/a 13.8 3.56 n/a
King Pharmaceuticals KG 9.40 2,330.0 n/a 9.4 1.49 n/a
Mylan Inc. MYL 12.94 3,950.0 19.09 8.92 0.75 n/a
Industry Median 17.42 n/a 4.36 n/a

Generex Biotechnology Corp. GNBT 0.65 119.4 n/a n/a 110.77 n/a
Source: Thomson Financial
Insider Trading Activity

NET SHARE PURCHASE ACTIVITY

Insider Purchases - Last 6 Months
Shares Trans
Purchases 12359 1
Sales n/a 0
Net Shares Purchased (Sold) 12,359 1
Total Insider Shares Held 3.90M n/a
% Net Shares Purchased (Sold) 0.30% n/a

Net Institutional Purchases - Prior Qtr to Latest Qtr
Shares
Net Shares Purchased (Sold) (207,149)
% Change in Institutional Shares Held (6.3%)

Data provided by Thomson Financial

[waxweazle]

Antwort auf Beitrag Nr.: 37.655.018 von waxweazle am 27.07.09 20:13:44

Generex Announces Plans to File An Investigational New Drug (IND) With the Veterinary Drugs Directorate of Health Canada in Anticipation of a New Drug Submission for Generex Oral-lyn(tm)
Pre-NDS Meeting Held With Health Canada

* Press Release
* Source: Generex Biotechnology Corp.
* On Wednesday July 22, 2009, 9:30 am EDT

*
Buzz up! 0
* Print

*
Companies:
o Generex biotechnology corp.

WORCESTER, Mass., July 22, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News; www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that the Company held a meeting with the Veterinary Drugs Directorate (VDD) of Health Canada on July 14th in Ottawa, Canada. The meeting was a Pre-New Drug Submission (NDS) meeting for the purpose of outlining the Company's proposed development plan for the veterinary application of Generex Oral-lyn, the Company's proprietary oral insulin spray product, with a view to proceeding with the filing of an NDS. As a result of this meeting, the Company plans to prepare an IND package for submission to the VDD before the end of this year.
Related Quotes
Symbol Price Change
GNBT 0.6837 +0.0296
Chart for Generex Biotechnology Corporati
{"s" : "gnbt","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Anna Gluskin, the Company's President & Chief Executive Officer, commented: "We are delighted to have made the necessary progress to further establish our plans for our flagship product, Generex Oral-lyn(tm), in the veterinary field. This step is very important in that it paves the way for improved treatment for companion dogs (and later cats) suffering from diabetes. Generex Oral-lyn(tm) will provide a more user-friendly option to pet owners and encourage compliance."

To date, the company has conducted a two-year safety study on dogs as well as drafted a preliminary clinical design in order to meet some of the regulatory requirements for the IND application.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.

The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Contact:

American Capital Ventures, Inc.
Investor Relations Contact:
Howard Gostfrand
1-877-918-0774

Beckerman Public Relations
Media Contact:
Angelene Taccini
201-465-8024

[Caravest]

Antwort auf Beitrag Nr.: 37.655.093 von waxweazle am 27.07.09 20:23:03

Gute Idee. Danke. Ich werde den Thread mit Interesse verfolgen.

Gruss
Caravest

[waxweazle]

Share Statistics
Average Volume (3 month)3: 10,298,900
Average Volume (10 day)3: 5,459,230
Shares Outstanding5: 183.62M
Float: 176.99M
% Held by Insiders1: 2.12%
% Held by Institutions1: 1.90%
Shares Short (as of 25-Jun-09)3: 4.53M
Short Ratio (as of 25-Jun-09)3: 0.5
Short % of Float (as of 25-Jun-09)3: 2.50%
Shares Short (prior month)3: 3.08M

[waxweazle]

[waxweazle]

wow seit Posting hier waren wir noch unter 70 cent

[waxweazle]

erwähnung im im Threat war bei ca. 0.68 cent



70 war der Breakout Point könnte noch ein retest geben und danach weiter hoch

[waxweazle]

Antwort auf Beitrag Nr.: 37.655.217 von waxweazle am 27.07.09 20:37:30

Untertassenformation

Eine selten anzutreffende Trendumkehrformation der technischen Analyse, bei der sich die Abwärtsbewegung verlangsamt, zum Stillstand kommt und ganz allmählich nach oben zieht. Am rechten Rand der Untertasse bildet sich unter Umständen noch eine kleine Plattform.

[waxweazle]

schade JAZZ habe ich zu sät gesehen ist aus einem Dreieck ausbebrochen danach gings heftig hoch
ISIN

US4721471070

[waxweazle]

GNBT



Neues hoch ..
gar net schlecht seit einstellung hier von 68 cent auf aktuell 73,4 cent

[bernim1508]

Hi Wax,


glaubst Du wir sehen nächste Woche die $ 1,00?


Gruss

[waxweazle]

Schluss auf Tageshoch

[waxweazle]

Antwort auf Beitrag Nr.: 37.655.993 von bernim1508 am 27.07.09 22:13:29

solche Prognosen sind immer schwierig der Chart sieht gut aus!!
das kann ich halt sagen...

[bernim1508]

Gruss,

nimmst Du für deine Prognosen immer MACD, STOCH?

Kann man wegen den BB auch sagen das ist eine Trendwende?


Gruss

[waxweazle]

Antwort auf Beitrag Nr.: 37.657.402 von bernim1508 am 28.07.09 09:19:42

Ich nehme normalerweise die einfachen Indikatoren schau mir die anderen auch an. Aber in den CHarts die ich poste nehme ich die einfachsten weil sonst wir es unübersichtlich..


Bollinger Band
Hier wird ein gleitender Durchschnitt berechnet, um den herum zwei Umhüllungslinien konstruiert werden. Im Gegensatz zu den Envelopes orientiert sich der Abstand der Bollinger Bands um den gleitenden Durchschnitt nicht an einen bestimmten Prozentsatz sondern ausschließlich an der Standardabweichung bzw. der Volatilität des Basistitels.

- Der Kurs neigt im Allgemeinen dazu, sich von einem Bollinger Band zum nächsten zu bewegen. Dies erlaubt Rückschlüsse zur Kurszielbestimmung.
- Wenn sich beide Bollinger Bands dem gleitenden Durchschnitt annähern (dh. geringe Volatilität vorherrscht), steht oft eine nachhaltige Kursbewegung bevor.
- Ein Ausbruch aus den Bollinger Bands läßt eine Fortsetzung der Kursbewegung in Richtung des Ausbruchs erwarten; dies gilt insbesonders, wenn die Bollinger Bands zum Zeitpunkt des Ausbruchs nahe ihrem gleitenden Durchschnitt waren.

auf weiter steigende Kurse
wax

[bernim1508]

Antwort auf Beitrag Nr.: 37.658.024 von waxweazle am 28.07.09 10:21:19

THX


bin noch relativ am Anfang was die Chartlehre betrifft.


Gruss

[waxweazle]

aktuell retest des Ausbruchs...

[waxweazle]

Heute rennt XOMA nächster wichtiger Punkt zum Brechen 0.91

[waxweazle]

XOma sieht nach neuem hoch aus

[waxweazle]

sehr schön!! läuft gerade richtig geil!! jetzt die 91 cent und Squeeezz

[waxweazle]

Antwort auf Beitrag Nr.: 37.663.506 von waxweazle am 28.07.09 19:13:43

kaum gesagt schon passiert!

[microby]

xoma aktuell bei 0,94 usd

[waxweazle]

Xoma Schluss bei kanpp unter 1$ nice!!

[waxweazle]

GNBT nimmt nächsten Anlauf nach oben!!
Siehe erste Postings in diesem Threat

[waxweazle]

Antwort auf Beitrag Nr.: 37.671.081 von waxweazle am 29.07.09 17:05:04

Us Kürzel: CVM



Chart sieht gut aus Breakoutchart

[waxweazle]

CVM weekly

http://stockcharts.com/c-sc/sc?s=cvm&p=W&yr=1&mn=0&dy=0&i=p2…

[waxweazle]

Antwort auf Beitrag Nr.: 37.672.839 von waxweazle am 29.07.09 20:44:11

und schon 2 cent im Plus
Schluss über 50 cent wäre super

[waxweazle]

Gestern hier zu ca. 45 cent Empfohlen heute geht die durch die Decke

CVM

Who's Afraid of the Big Bad Flu? One company is diligently preparing for the worst case scenario with promising results.
Written by M.E.Garza
Wednesday, 29 July 2009 12:11

“…Off the record, in a deep conversation in a dark bar, a government scientist researching pandemic flu would say that they’re scared to death because they see just how intelligent this virus is…”

Like many of you, over the last few months, I’ve been drawn in by the alarming- often unnerving- headlines about the H1N1 flu pandemic.

“It’s all hype,” some say. “Don’t buy into what the establishment is selling. “

From the start, I couldn’t help myself from suspiciously scoffing at some of the ratings and readership driven headlines.

That all changed for me late last month when I decided to research what all this noise was really about.

Now, frankly, I wish I had been less overcritical and more ostrich-like. Some part of me wishes to rediscover the peace of mind that got lost since my journey to into the darkness of the coming flu pandemic and the brutal truth behind it.

That this is a space about biotech investing reminds me to tell you, my captive audience, that I’m very cognizant of that fact and that this isn’t going to turn into the type of exposé found in a sensational cheap magazine.

Better yet, I can tell you that this company is flying under the same radar screens that point the flock of eager investors into playing the “swine flu stocks.”

As with the rest of story, the truth is, there is much more substance than sizzle here.

As with the rest of the tale, there is also much more terror in the truth than I bargained for.

I realized early on that if I were to get anywhere near the truth about H1N1, my first challenge was to find someone trustworthy and experienced who could help point the way. I needed to clear my already cynical mind from further clouding.


H1N1 Vaccine Shortage Possible
KMSP FOX 9 Minneapolis | Jul. 29, 2009






I began to scour the Centers for Disease Control and Prevention website and found various estimates of flu-related deaths (since apparently there is no true method or count for these deaths) and experts there will tell you that the actual number of deaths vary greatly from year to year because flu seasons often fluctuate in length and severity.

I found alarming press clippings from the U.S. Military stating that they are confident that years of pandemic planning will help it deal with H1N1. Those of us who watched the events surrounding Hurricane Katrina and our national government’s reactions can rest easy now, right?

I dug deeper.

I connected to someone who has spent twenty-five years working on biopharmaceutical development and regulatory issues in the U.S. He also spent the last quarter of a century working on various therapeutic and preventative platforms as well as vaccines, but he would only speak to me on the record under strict conditions of anonymity.

Having taken part in many collaborations with the government at various levels with several agencies, he wanted the public to know the truth, but he was also not thrilled by the idea of being castigated or confused in any way with chicken little.

After a brief pause, I slipped on my best Woodward and Bernstein and told him I’d agree to his conditions.

“The biggest concern is to ask ourselves what this is and how is it being addressed, “ he began.

“ There are some great limitations of existing technologies and approaches that are being used currently and that have been used historically. Where they’ve got the biggest challenge from a public health perspective is that these methods are all backwards looking, and we’re using a strain of this virus that is a strain that was identified at the end of April in California.”

While that’s not unimportant – since this is the strain of the virus that is currently plaguing the United States and pretty much the entire rest of the globe- the CDC and the scientific community have pointed out consistently that, as is always the case with influenza generally, this virus is inherently unstable. It mutates.

“That’s precisely why we’ve got this particular strain- one that, despite it being summer in the northern hemisphere- is still propagating and still causing significant morbidity and a fair amount of mortality, which is highly unusual,” he explained calmly.

“Obviously it’s also circulating in the Southern Hemisphere, but at some point, consistent with the variations that we’ve already seen with this virus in terms of Tamiflu resistance, this virus is going to- for lack of a better word- mutate again and how it will change and how it will present itself going forward is totally unpredictable.”

What is known about influenza viruses is that as they evolve and when they genetically alter through the process of resortment , natural selection principles tell us that the viruses look to alter in ways that continue to maintain their ease of transmissibility and certainly their morbidity potential.

“In an ideal world, the ideal virus doesn’t try to wreak mass mortality because at some point if it’s killing its hosts, its own ability to survive is compromised, but this virus obviously has been smart enough to figure out how to survive in the summer heat when it usually survives in the winter cold. It has figured out how to transmit from human to human on a global basis faster than any influenza virus before. Part of that is a reality of the current global marketplace and its global transportation modes, but it’s also a reflection of the virus.”

This guy may have been shy, but he didn’t mince any words.

“There are obviously other influenza viruses on the planet that are known and some that are probably unknown and as, we look forward, all the approaches right now are focused on that California strain- which in essence is the same strain that originated down in Mexico. As we look forward, as this virus continues to circle the globe, as it interfaces in humans and more importantly in pigs, there is a significant chance that it will evolve and could soon have greater morbidity effects and far worse mortality effects on the global population, comparable to what happened in 1918 – which also involved an H1N1 virus. With the last recirculating H1N1 being in 1957, the global population’s level of natural immunity may be assumed to be low.”

In looking at the approaches on the table today, scientists and pharmaceutical companies are simply trying to give us vaccines that look at building up immunity against only that original strain, and while that is all well and good, a basic problem remains.

“It’s a critically-important step that must be taken but it’s still backwards looking, not forward looking, and those vaccines cannot and do not anticipate future variations that occur through natural selection, especially as a result of resortment. So in essence, we hope to have a vaccine that will protect against this virus as it was discovered in late-April and exists now, but it’s ability to protect against the evolution of this virus is pretty much non-existent- especially if we end up with yet another entirely new strain that has greater virulence.”

That sobering, if not shocking dose of the truth led me to dig further and eventually to the doorsteps of the CEL-SCI Corporation (Amex: CVM) and it’s CEO, Geert Kersten.

Kersten has been with CEL-SCI from the early days of its inception in the late 80’s. And for better or worse, he’s been involved in the pioneering field of cancer immunotherapy for almost two decades, through its many challenging cycles.

“The government needs to continue doing what it’s doing, because that’s their job,” says Kersten in a calm voice layered with his thick, native German accent. “But at the same time, no one is addressing the issue of a more dangerous, yet very likely, mutated virus. What happens when it stops responding to Tamiflu or Relenza ? ”

Good questions, indeed.

Just five years ago, Relenza- the influenza treatment developed in Australia- was headed for the drug scrapheap. Today, as the world scrambles to cope with the flu pandemic, suddenly Relenza is headed for "blockbuster" status and that’s a term which is reserved for drugs that generate over $1 billion a year in sales. Mere days ago there were news headlines that GlaxoSmithKline (NYSE:GSK) is attempting to triple its global capacity in order to produce Relenza. Those efforts are going to justify its blockbuster tag with ease, but that’s only going to work for so long.

“If something knocks out the virus’ ability to survive, it will, by definition, following ‘selfish gene’ theory, continue to evolve and figure out a way to work around that imposition.” I am reminded by my biologic informant.

In other words, it will genetically modify itself and circumvent the vaccines, as well as the Tamiflus and Relenzas.

“Since this is such a doomsday scenario, shouldn’t we be taking out some insurance?” asks CEL-SCI’s Kersten. “

CEL-SCI’s preclinical studies have demonstrated that vaccines utilizing its proprietary L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology potentially induce protection against illnesses such as the swine influenza. L.E.A.P.S. helps direct the immune response to the vaccine epitope.

What his company’s technology proposes is the ability to attack what comes out of those mutations the moment it shows up, as opposed to what we have now.

“The idea is very simple, if I’m looking for a bad guy and I know that bad guy is going to undergo facial reconstruction or hair color changes, the only way I’m going to be able to capture that bad guy is by focusing on parts of that person that cannot be changed,” explains Kersten.

“While he can wear colored contact lenses on his eyes, he can’t actually change his eyes. So if I have a biometric measurement machine that checks for eyes as he walks past it, then no matter what he’s done, he cannot escape from me. Much like that analogy, there are various parts of the virus that are central to its survival. The virus mutates in order to defend itself and those regions which mutate are actually the easiest target for vaccine development. They ‘stand out.’ It’s almost like a ruse that the virus creates to divert you from parts of itself that are important to survival, so the current vaccine development focuses on the easy targets and you get strong immune responses to them, but then the virus mutates and the vaccine doesn’t work anymore.

“Our work is different. We focus on parts of the virus that may not make for targets that are as easy as the current ones but they cannot change because if they change the virus simply dies. So if you now make a combination of these parts and you take them from the current swine flu, you move forward knowing that the mutated swine flu will have the same parts that will remain unchanged. Then you add to that some parts from, say, the current avian flu. And you take another from the Spanish flu [the 1918 pandemic also was caused by an H1N1]. You end up with several peptides mixed to form one vaccine which should provide at least partial protection and treatment against a mutated virus which itself has taken different pieces from different viruses and put them together.”

The key focus of the L.E.A.P.S. technology approach is that it’s selecting common regions across a range of viruses that through the course of time have shown high virulence, high morbidity, and high mortality and then helps the immune system process these regions in a manner that will lead to clinical benefit, whether that is prevention or treatment. It uses non changing parts of the viruses as a base for constructing a treatment paradigm or a preventative paradigm. The technology could potentially be used in either or both contexts. By having those common foundational elements, there is a much greater likelihood to be able to catch up , stay current with and even at some levels stay ahead of the virus as it goes through both global circulation and a resortment process, especially in the context of H5N1 or any of the other influenzas that we know about, or more importantly that we don’t know about.

That work is not that expensive. It involves peptides and other technologies that, for a little bit of money, could potentially forestall an apocalyptic type of disaster.

“One of the fascinating things that the media and most everyone else pays no attention to is that early on, very early on, the CDC knew that there were problems growing this strain of virus used for the conventional vaccine approach now being ramped up for swine flu,” says my informant. “ The low yields and long time to production should not be news to anyone in the know. The current vaccine manufacturers have come out and said, ‘hey we’re getting low yields and its taking us a long time to produce that low-yielding vaccine,’ but insiders have known this since last April.

“This gets back to just how smart a virus we’re dealing with. To boil it down to simplistic almost cartoonish terms, this thing has figured out how to survive the environmental conditions in which influenza viruses have never survived, namely heat and humidity.

“It is contrary to all of influenza history to see a virus surviving the way this one is. It knows enough that vaccines- ever since we started creating vaccines- are produced in eggs and it’s genetic code knows enough not to allow a vaccine to be produced in eggs quickly. This is not by chance that we’ve got this problem. This all gets back to a virus that has been around for hundreds of years and through hundreds of years of experience has morphed itself into something that is wary of being trapped or deceived.

“It has figured out a way to continue its propagation almost unimpeded and that would suggest that off the record, in a deep conversation in a dark bar, a government scientist researching pandemic flu would say that they’re scared to death because they see just how intelligent this virus is, they see what it’s done already and they know its potential. It’s ability to have done what it’s already done suggests a genetic intelligence- a genetic code internal to the virus- that will allow it to adapt in ways in which we have not seen influenza adapt before. “

There are many more reasons to like CEL-SCI for the work they’re doing in the influenza space and beyond.
In the coming days I’ll continue to explore those reasons with you.

In the meantime, stay tuned and informed, and if you can help it all- stay protected.

Disclosure: No Positions

[main-maus]

Antwort auf Beitrag Nr.: 37.675.934 von waxweazle am 30.07.09 10:50:45

Danke, Wax. Eine Bitte: kannst du die Wwertpapierkennnummer mit angeben, das erleichtert die Suche.

[Tommi33]

Antwort auf Beitrag Nr.: 37.680.465 von main-maus am 30.07.09 18:02:41

Guck mal nach -> US1508374097

Oder wenn Kürzel auftaucht http://www.nasdaq.com/ und als Symbol das Kürzel eingeben falls w:o suche nichts ergibt.

LG Tommi

[waxweazle]

Antwort auf Beitrag Nr.: 37.683.307 von Tommi33 am 31.07.09 05:29:46

Danke dir !
XOMA und GNBT waren daytrading...

US1508374097
sieht weiter nett aus seit erwähnung waren wir schon mit knapp 20% im plus

[Eisenherz1]

Antwort auf Beitrag Nr.: 37.688.267 von waxweazle am 31.07.09 16:40:33

Hallo wax,
nach dem BREAKOUT am Freitag von OWVI wo siehst du kurzfristig das Ziel!?
Vielen Dank

Gruß Eisenherz

[waxweazle]

Antwort auf Beitrag Nr.: 37.697.779 von Eisenherz1 am 03.08.09 11:50:15

OWVI 0.003 sollten man nehmen damit mehr geht.. wenn die genommen werden ist theoretisch bis 1 cent platz

[waxweazle]

Hier mal eine ehr long long Aktie

Marktkapital.

67,02 Mio. USD

Streubesitz

--

Nennwert

--

Stücke

45 Mio.

Symbol

CWSI.NAP

ISIN

US16945F1003

WKN

A0NATX



WIndkraft China

Stellt für Windkrafanlagen Materialien her...
weiter Infos unter yahoo da stehen auch die neuesten News!

[waxweazle]

watch
CERS + ARIA zum traden

cers
WKN: 905249



ARIA
WKN: 895301

[Peedy2003]

Antwort auf Beitrag Nr.: 37.700.096 von waxweazle am 03.08.09 16:14:11

Hallo Wax,

wie siehst Du den weiteren Verlauf von Generex Biotech?
Hattest Du ja mal hier empfohlen.

Gruß Peedy.

[waxweazle]

Antwort auf Beitrag Nr.: 37.700.220 von Peedy2003 am 03.08.09 16:25:29

Also die 0.59 us cent sollte halten sonst sieht es nicht mehr gut aus...
Ist alles rein charttechnisch...
Die Aktien hier sind meist rebound oder Breakout Aktien..

[waxweazle]

XTENT
Intraday-Chart
WKN: A0LBTT
ISIN: US9841411013
Symbol: XEC

heute Conferenc Call könnte Interessant werden..

[waxweazle]

Antwort auf Beitrag Nr.: 37.700.340 von waxweazle am 03.08.09 16:35:50

XTNT
hier nachzulesen allerdings high risk

http://www.wallstreet-online.de/diskussion/1150858-161-170/x…

[waxweazle]

Antwort auf Beitrag Nr.: 37.700.096 von waxweazle am 03.08.09 16:14:11

sehen beide weiter gut aus!

[waxweazle]

Breakoutplay

Marktkapital.

37,99 Mio. USD

Streubesitz

--

Nennwert

--

Stücke

17 Mio.

Symbol

PRLS.NAS

ISIN

US7055361007

WKN

902999

[waxweazle]

jetzt was für unsere Pennytrader OWVI rennt seit Empfehlung zu 0.0012
und jetzt

Symbol

PINR.NOO

ISIN

US7227671002

WKN

B1VTVF4

Morgen Symbole change + neues Bussines + kein reverse split!!

[waxweazle]

Antwort auf Beitrag Nr.: 37.711.461 von waxweazle am 04.08.09 22:44:08

MIKP vorher PINR schon schön im Plus

50% Plus wird der nächste 10 bagger hier..

[Eisenherz1]

Antwort auf Beitrag Nr.: 37.717.525 von waxweazle am 05.08.09 17:35:44

Hallo wax,
was hälst du von ICTY?

[Eisenherz1]

Guten Morgen wax,
MESA ist gestern ausgebrochen!
Sieh dir den Chart an!

[waxweazle]

Antwort auf Beitrag Nr.: 37.729.355 von Eisenherz1 am 07.08.09 08:26:50

hi sieht sehr interessant aus Danke dir!!!

#43 von waxweazle Benutzerinfo Nachricht an Benutzer Beiträge des Benutzers ausblenden 04.08.09 14:48:32 Beitrag Nr.: 37.707.250

ISIN

US7055361007

Ist bisher gut gelaufen und nach oben ausgebrochen...


Pennystocks die heute Interessant sind:

SARO, ARIO, MIKP

Watch OWVI , MESA , ICTY

[waxweazle]

[waxweazle]

SARO NEWS - SEATTLE, Aug. 7, 2009 (GLOBE NEWSWIRE) -- SARS Corporation (Pink Sheets:SARO - News), a Nevada corporation d/b/a FasTech Holdings, Inc. ("FasTech" or the "Company"), today announced that it has retained Clayton Shelver as Executive VP/CTO, with the specific responsibility to facilitate the company's planned expansion of its building energy management and controls services and business. Mr. Shelver is currently ushering FasTech through the process of obtaining certifications with several, worldwide providers of building control systems, and expects to complete the initial certifications within the next several weeks.

Shelver, formerly a CTO of SARS who brings over 20+ years of IT management and systems monitoring experience, will provide FasTech with management and understanding of how to utilize and integrate systems controls, asset information, and information systems for both the company and its customers. FasTech expects that Shelver's professional background will enable FasTech, through remote asset monitoring and control, to measurably increase services in energy efficient building management and controls, a field which includes everything from programmable building temperature controls to comprehensive technology that can monitor, measure, and control hundreds of HVAC systems and devices remotely. Assets are considered "remote" if outside the immediate view of the person responsible for managing them, and are typically appropriate for remote management if they are high-value assets, and/or ones that can need schedule, operating status, environmental conditions status, and notification of "condition change" status.

In addition to providing services on new construction, Shelver and the FasTech team will work with controls products that are "open" software platform -- typically based on the industry software standard called BACnet(tm) -- and ones that can be configured to use any communications service or hardware. This will allow FasTech to integrate with existing competitive control systems and to market remote monitoring services to already-constructed and operating facilities. These FasTech monitoring services offer building owners and operators a variety of benefits, including reduced operating costs, protection of current system investments and increased equipment life, lowered maintenance costs, rapid problem identification, and improved operating efficiency.

Said Frank Bonadio, FasTech President and CEO: "We're delighted to have Clayton join our team of systems professionals. His prior monitoring experience with SARS allows us to take advantage of a growing opportunity in building energy management in the MidWest and beyond. We work with a large base of aging buildings, hospitals, schools, etc. -- all of which must be maintained or upgraded due to their general condition and to hold back the effect of dramatically rising utility costs. Adding new construction opportunities to that, we see energy management as a natural and profitable extension of our design and construction businesses."

Shelver added: "Energy controls and systems monitoring/management are clearly fields that represent tremendous future financial growth and opportunity for FasTech. I look forward to working with Frank and the entire group to secure as much of that business as possible."

FasTech recently commenced the process of formerly changing its name from SARS Corporation to "FasTech Holdings, Inc."


und hab das gefunden :


** SARO Charttechnical 08/06/09 **


http://i28.tinypic.com/15o9lqo.png

[stockventure]

Der Thread gefaellt mir...Danke!

[waxweazle]

Antwort auf Beitrag Nr.: 37.729.355 von Eisenherz1 am 07.08.09 08:26:50

Measa war net schlecht leider kein Geld frei gehabt

[waxweazle]

Antwort auf Beitrag Nr.: 37.798.236 von waxweazle am 17.08.09 22:14:58

hab mir heute für alle pennytrader OCFN gekauft ist ein Lowfloater mit OS 20 mille und AS ca. 6 Mille

ISIN

US68207V2088

gruss
wax

[Eisenherz1]

Antwort auf Beitrag Nr.: 37.798.289 von waxweazle am 17.08.09 22:21:53

seht euch mal EPAZ (OTCBB) an.

laut TA vom 22.07.09
A/S: 60 Mil.
O/S: ca. 53 Mil.
Float: 22,5 Mil.

Gruß Eisenherz

[waxweazle]

Antwort auf Beitrag Nr.: 37.799.176 von Eisenherz1 am 18.08.09 08:30:27

QASP

hier sollen 3 Aquisitionen kommen am 28. letzt pr lesen etc.


gruss
wax

[waxweazle]

Antwort auf Beitrag Nr.: 37.799.176 von Eisenherz1 am 18.08.09 08:30:27

schau ich mir mal an was wichtig ist:

ob ne story dahinter istdie gekauft werden könnte..
wie bei jeder pinki bzw. otcbb werten

[waxweazle]

Vonage Announces Unlimited Flat Rate Calling Around the World and Readable Voicemail For $24.99/MO
-Unlimited Calling to More Than 60 Countries and the U.S.- -Readable Voicemail Delivered to PC or Mobile Phone-

* Press Release
* Source: Vonage
* On Thursday August 20, 2009, 8:30 am EDT

o
Buzz up! 2
o Print

*
Companies:
o Vonage Holdings Corporation

HOLMDEL, N.J., Aug. 20 /PRNewswire-FirstCall/ -- Today, Vonage introduced two new services that dramatically improve the value of its core offering. "Vonage World," provides unlimited calling around the world to more than 60 countries, including India, Mexico and China for the current flat monthly rate of $24.99.

In addition, the new Vonage Visual Voicemail service extends the company's presence onto other devices by providing unlimited "readable voicemail" delivered via email or SMS text message. Vonage is the only U.S. home phone service provider to offer voice-to-text conversion at no additional charge. Both services will become basic features of the core Vonage offering.

"Vonage recognizes that everyone has communication needs that extend beyond the walls of their homes; and many of our customers live in communities with borders that extend beyond the U.S. We have created Vonage Visual Voicemail and Vonage World to enable customers to stay connected to the people they care about, whether they are down the street or across an ocean," said Marc Lefar, CEO of Vonage. "These new services continue our tradition of using technology to create high value and affordable prices to our current and future customers."

Vonage World includes unlimited calling to countries representing approximately 65% of the world's population (4.5 billion people). The international calling plans of most competitors are limited to certain locations within a country. However, the countries included in Vonage World are covered completely.

In response to customer demand for an improved way to access voicemail, Vonage is providing Vonage Visual Voicemail at no additional charge for Vonage World customers. This service makes voicemail readable by converting each message to text, giving customers the flexibility of viewing their voicemail as an email or SMS message on their computer or mobile device. Customers still have the option to listen to their voicemail over the phone if they choose.

Vonage World details are available at www.vonage.com or by calling [phone]. To follow Vonage on Twitter, please visit www.twitter.com/vonage_voice. Become a fan of Vonage on Facebook by going to www.facebook.com/vonage.

*Complete Chart of Available Countries/Territories

Andorra Cyprus India** Monaco Singapore**
------- ------ ------ ------ ----------
Argentina Czech Republic Iraq Netherlands Slovakia
--------- -------------- ---- ----------- --------
Australia Denmark Ireland New Zealand Slovenia
--------- ------- ------- ----------- --------
Austria Dominican Israel Norway South Africa
Republic
------- -------------- ------- ----------- ------------
Bahamas** Estonia Italy Peru South Korea
-------- ------- ----- ---- -----------
Bahrain France Japan Poland Taiwan
------- ------ ----- ------ ------
Belgium Finland Jordan Portugal Thailand**
------- ------- ------ -------- ---------
Brazil Georgia Kenya Puerto Rico** Turkey
------ ------- ----- ------------ ------
Brunei** Germany Latvia Romania United Kingdom
------- ------- ------ ------- --------------
Bulgaria Greece Luxembourg Russia United States**
-------- ------ ---------- ------ --------------
Canada** Guadeloupe Macau** Spain U.S. Virgin
Islands**
-------- -------------- ---------- ------------- ---------------
Chile Guam** Macedonia Sweden Venezuela
----- ----- --------- ------ ---------
China** Hong Kong** Malaysia** Switzerland Zambia
------ ---------- --------- ----------- ------
Colombia Hungary Malta Saipan**
-------- ------- ----- -------
Croatia Iceland Mexico San Marino**



** Includes calls to mobile phones

Technorati Tags: Vonage, International Calling, Business, Mobile, Technology, VoIP, Home, Phone Service, Phone Plan, Ex-Pat, Call Fees, Call Tariffs, International, Voice-to-Text, SMS, Visual Voicemail

About Vonage

Vonage (NYSE: VG - News) is a leading provider of broadband telephone services with approximately 2.5 million subscriber lines. Our award-winning technology enables anyone to make and receive phone calls with a touch tone telephone almost anywhere a broadband Internet connection is available. We offer feature-rich and cost-effective communication services that offer users an experience similar to traditional telephone services.

Our Vonage World and Small Business Unlimited calling plans offer consumers unlimited local and long distance calling, and popular features like call waiting, call forwarding and voicemail -- for one low, flat monthly rate.

Vonage's service is sold on the web and through national retailers including Best Buy and Wal-Mart Stores Inc. and is available to customers in the U.S., Canada and the United Kingdom. For more information about Vonage's products and services, please visit http://www.vonage.com.

Vonage Holdings Corp. is headquartered in Holmdel, New Jersey. Vonage® is a registered trademark of Vonage Marketing Inc., a subsidiary of Vonage Holdings Corp.

Vg-a

hier könnte bald was gehen

[waxweazle]

Antwort auf Beitrag Nr.: 37.822.219 von waxweazle am 20.08.09 23:00:26

VG ist explodiert hffe ein paar wearen dabei und hBEN NICHT vergessen heute zu verkaufen...

400% waren da drin




watchlist
CHCI

[waxweazle]

mich gibt es seit heute auch hier :

https://twitter.com/wax_weazle